Business
Kalytera Announces Notice of Allowance of EU Patent for Prevention and Treatment of Graft Versus Host Disease
Kalytera Announces Notice of Allowance of EU Patent for Prevention and Treatment of Graft Versus Host Disease.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\n SAN FRANCISCO and TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the \"Company\" or \"Kalytera\") is pleased to announce that the European Patent Office has issued a Notice of Allowance for EU Patent Application Number 14791611.8 covering the use of cannabidiol (“CBD”) in the treatment of graft versus host disease (“GVHD”). Kalytera has exclusive worldwide rights to this patent through an Exclusive License Agreement with MOR Research Applications, Ltd. of Israel. Securing a European patent for this proprietary technology represents an important step forward for Kalytera in its program to develop and commercialize CBD for prevention and treatment of this serious and life-threatening disease. “We are delighted to receive this Notice of Allowance from the European Patent Office,” said Robert Farrell, J.D., Kalytera’s President and Chief Executive Officer. \"Patients receiving bone marrow transplants are at high risk of developing acute GVHD, a complication that occurs when the transplanted donor cells attack the patient’s organs, including the skin, GI tract, liver, lungs, and eyes. There are currently no FDA approved therapies for the prevention of acute GVHD.” To complete the procedures for issuance of this EU patent, Kalytera must prepare and file translations of the patent claims into French and German. Kalytera will complete these procedures prior to the January 2020 deadline, and expects that the EU patent will issue shortly thereafter. This will be the third issued patent that Kalytera will have received for the use of CBD in the prevention and treatment of GVHD. In April and May last year, Kalytera announced that it had received notice of issuance from the U.S. Patent and Trademark Office for its two U.S. patents covering the use of CBD in the prevention and treatment of GVHD. In addition to its U.S. and EU patents, Kalytera has also obtained four orphan drug designations for the treatment and prevention of GVHD in the U.S. and Europe. Kalytera acquired its program in the prevention and treatment of GVHD in February 2017 through the acquisition of Talent Biotechs, Ltd. of Israel (“Talent“). Under its agreement with the former Talent shareholders, Kalytera is obligated to make additi...